Literature DB >> 12103369

Completion pneumonectomy for non-small cell lung cancer: experience with 59 cases.

A Terzi1, A Lonardoni, G Falezza, P Scanagatta, A Santo, G Furlan, F Calabrò.   

Abstract

OBJECTIVE: The objective of this study was to assess the results of completion pneumonectomy performed for non-small cell lung cancer, classified as second primary or recurrence/metastasis.
METHODS: From 1982 to 2000, 59 patients underwent completion pneumonectomy for lung cancer, classified second primary or recurrence/metastasis according to a modified form of Martini's criteria, after a mean interval from first resection of 60 months for second primary lung cancers and 19 months for recurrences/metastases.
RESULTS: Operative mortality was 3.4% and complications occurred in 30% of patients. Five-year survival rate for completely resected patients was 25% (median 20 months). No significant difference in long-term survival was detected between second primary and recurrent tumors; survival was not adversely affected by a resection interval of less than 2 years or less than 12 months.
CONCLUSIONS: Completion pneumonectomy for non-small cell lung cancer is a safe surgical procedure in experienced hands; long-term survival is acceptable and the best results are obtained for stage I lung cancer. Distinction between second primary lung cancer and recurrence failed to demonstrate a prognostic value.

Entities:  

Mesh:

Year:  2002        PMID: 12103369     DOI: 10.1016/s1010-7940(02)00242-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Surgical resection of recurrent lung cancer in patients following curative resection.

Authors:  Hyoung Soo Kim; Hoseok I; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Jhingook Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

2.  Completion pneumonectomy: outcomes for benign and malignant indications.

Authors:  Varun Puri; Andrew Tran; Jennifer M Bell; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2013-05-03       Impact factor: 4.330

3.  Emergent completion pneumonectomy for postoperative hemorrhage from rupture of the infected pulmonary artery in lung cancer surgery.

Authors:  Takanori Ayabe; Tetsuya M Shimizu; Masaki Tomita; Mitsuhiro Yano; Kunihide Nakamura; Toshio Onitsuka
Journal:  Case Rep Surg       Date:  2011-07-31

4.  Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries.

Authors:  Dragan Subotic; Laureano Molins; Ivan Soldatovic; Dejan Moskovljevic; Lucia Collado; Jorge Hernández
Journal:  World J Surg Oncol       Date:  2018-05-28       Impact factor: 2.754

5.  Completion Pneumonectomy for Non-Small-Cell Lung Cancer: Does Induction Treatment Influence Postoperative Outcomes?

Authors:  Domenico Galetta; Lorenzo Spaggiari
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

6.  Completion pneumonectomy: Indications and outcomes in non-small cell lung cancer.

Authors:  Serkan Yazgan; Ahmet Üçvet; Soner Gürsoy; Özgür Samancılar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-09-16       Impact factor: 0.332

7.  Completion pneumonectomy for lung cancer treatment: early and long term outcomes.

Authors:  Peng Zhang; Chao Jiang; Wenxin He; Nan Song; Xiao Zhou; Gening Jiang
Journal:  J Cardiothorac Surg       Date:  2012-10-09       Impact factor: 1.637

8.  Completion pneumonectomy and chemoradiotherapy as treatment options in local recurrence of non-small-cell lung cancer.

Authors:  Mariusz Kasprzyk; Grzegorz Sławiński; Martyna Musik; Łukasz Marciniak; Wojciech Dyszkiewicz; Cezary Piwkowski; Bartłomiej Gałęcki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-03-31

9.  Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer.

Authors:  Kyung Hwa Lee; Yong Chan Ahn; Hongryull Pyo; Jae Myoung Noh; Seung Gyu Park; Tae Gyu Kim; Eonju Lee; Heerim Nam; Hyebin Lee; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Cancer Res Treat       Date:  2018-09-11       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.